ActiGraph, a leading provider of objective physical activity and sleep/wake monitoring solutions for the global research community, announced today the release of an Application Programming Interface (API) to its popular ActiLife analysis software. The newest addition to ActiGraph’s growing technology suite, the ActiLife API was designed to run within closed systems, ensuring that protocol and regulation compliance requirements are not compromised during data collection.
ActiGraph’s new API allows programmatic control of the ActiLife software over a standard socket, allowing users to develop their own custom applications (Java, C#, C++, etc.) which can automate activity monitor deployments and downloads. An active Internet connection is not required and the ActiLife user interface control can be completely blocked from view, allowing full integration and automation of custom client applications. The ActiLife API currently supports all ActiGraph devices, including the company’s newest wireless wGT3X+ and wActiSleep+ monitors.
“The ActiLife API was primarily developed to support the implementation of ActiGraph’s objective monitoring system within drug trials and clinical research studies,” said Jeremy Wyatt, ActiGraph’s Vice President of Software Engineering. “The tremendous value of objective measures within these markets is finally becoming fully understood, and we are focused on developing tools, like the ActiLife API, that deliver data seamlessly in these complex environments.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.